Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK

被引：0
|
作者：
Mughal, F. [1 ]
Barker, J. [2 ]
Cawston, H. [3 ]
Damera, V. [3 ]
Bewley, A. [4 ,5 ]
Morris, J. [6 ]
Shaw, T. [7 ]
Tencer, T. [8 ]
Zhang, F. [8 ]
机构：
[1] Celgene Ltd, Uxbridge, Middx, England
[2] St Johns Inst Dermatol Kings Coll, London, England
[3] Mapi Grp, London, England
[4] Whipps Cross Univ Hosp, London, England
[5] Royal London Hosp, London, England
[6] Cogentia Healthcare Consulting, Cambridge, England
[7] Celgene Ltd, Southall, Middx, England
[8] Celgene Corp, Summit, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2016年 / 175卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
    Jinsui Zhang
    Zemin Xia
    Wanjie Guo
    Xiaoxiao Ren
    Fang Liu
    Gargi Ratnaparkhi
    Amit Pagada
    Subhashini Subramanian
    Min Hu
    Wen Chen
    Dermatology and Therapy, 2023, 13 : 2681 - 2696
  • [42] A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
    Gabrielle Becher
    Sophia Conner
    Jennifer A. Ingram
    Karen E. Stephen
    Alison C. McInnes
    Adrian H. Heald
    Paul A. Riley
    Mark Davies
    Arnau Domenech
    Ismail Kasujee
    Dermatology and Therapy, 2022, 12 : 2343 - 2354
  • [43] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ITALIAN SETTING
    Barbieri, M.
    Capri, S.
    Oskar, B.
    VALUE IN HEALTH, 2015, 18 (07) : A419 - A420
  • [44] Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis
    Aljefri, Yara E.
    Ghaddaf, Abdullah A.
    Alkhunani, Tala A.
    Alkhamisi, Taif A.
    Alahmadi, Rana A.
    Alamri, Awadh M.
    Alraddadi, Ali A.
    DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [45] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [46] Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
    Heydendael, VMR
    Spuls, PI
    Opmeer, BC
    de Borgie, CAJM
    Reitsma, JB
    Goldschmidt, WFM
    Bossuyt, PMM
    Bos, JD
    de Rie, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 658 - 665
  • [47] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Gooderham, Melinda
    Li, Qing
    Cichanowitz, Nicole
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226
  • [48] Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
    Verbenko, Dmitry A.
    Karamova, Arfenya E.
    Artamonova, Olga G.
    Deryabin, Dmitry G.
    Rakitko, Alexander
    Chernitsov, Alexandr
    Krasnenko, Anna
    Elmuratov, Artem
    Solomka, Victoria S.
    Kubanov, Alexey A.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (01): : 1 - 12
  • [49] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [50] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
    Kory P. Schrom
    Avi Bitterman
    Neil J. Korman
    Current Dermatology Reports, 2019, 8 : 6 - 13
12345